A detailed history of Natixis Advisors, L.P. transactions in Abb Vie Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 1,213,411 shares of ABBV stock, worth $218 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
1,213,411
Previous 1,153,254 5.22%
Holding current value
$218 Million
Previous $198 Million 21.14%
% of portfolio
0.47%
Previous 0.43%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$163.84 - $199.33 $9.86 Million - $12 Million
60,157 Added 5.22%
1,213,411 $240 Million
Q2 2024

Aug 01, 2024

BUY
$154.79 - $180.76 $10 Million - $11.7 Million
64,844 Added 5.96%
1,153,254 $198 Million
Q1 2024

Apr 25, 2024

BUY
$159.82 - $182.1 $14.7 Million - $16.8 Million
91,985 Added 9.23%
1,088,410 $198 Million
Q4 2023

Feb 06, 2024

BUY
$137.6 - $154.97 $12.6 Million - $14.2 Million
91,525 Added 10.11%
996,425 $154 Million
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $36.5 Million - $42.3 Million
273,282 Added 43.27%
904,900 $135 Million
Q2 2023

Aug 15, 2023

SELL
$132.51 - $164.9 $13.9 Million - $17.3 Million
-105,179 Reduced 14.28%
631,618 $85.1 Million
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $8.41 Million - $9.68 Million
58,125 Added 8.56%
736,797 $117 Million
Q4 2022

Jan 27, 2023

BUY
$138.31 - $165.87 $1.95 Million - $2.34 Million
14,112 Added 2.12%
678,672 $110 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $11.9 Million - $13.6 Million
88,312 Added 15.33%
664,560 $89.2 Million
Q2 2022

Aug 12, 2022

SELL
$137.62 - $174.96 $3.51 Million - $4.46 Million
-25,472 Reduced 4.23%
576,248 $88.3 Million
Q1 2022

May 12, 2022

BUY
$131.98 - $163.75 $9.84 Million - $12.2 Million
74,571 Added 14.15%
601,720 $97.5 Million
Q4 2021

Feb 08, 2022

BUY
$107.43 - $135.93 $6.67 Million - $8.44 Million
62,096 Added 13.35%
527,149 $71.4 Million
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $711,496 - $807,655
-6,687 Reduced 1.42%
465,053 $50.2 Million
Q2 2021

Aug 12, 2021

BUY
$105.21 - $117.21 $5.01 Million - $5.58 Million
47,609 Added 11.23%
471,740 $53.1 Million
Q1 2021

May 05, 2021

BUY
$102.3 - $112.62 $4.33 Million - $4.77 Million
42,342 Added 11.09%
424,131 $45.9 Million
Q4 2020

Feb 12, 2021

SELL
$80.49 - $108.67 $5.84 Million - $7.88 Million
-72,528 Reduced 15.96%
381,789 $40.9 Million
Q3 2020

Nov 12, 2020

SELL
$85.91 - $100.83 $14.1 Million - $16.5 Million
-163,891 Reduced 26.51%
454,317 $39.8 Million
Q2 2020

Aug 11, 2020

BUY
$73.37 - $98.18 $4.03 Million - $5.4 Million
54,980 Added 9.76%
618,208 $60.7 Million
Q1 2020

Apr 27, 2020

SELL
$64.5 - $97.79 $8.99 Million - $13.6 Million
-139,441 Reduced 19.84%
563,228 $42.9 Million
Q4 2019

Feb 10, 2020

BUY
$72.13 - $90.25 $2.19 Million - $2.74 Million
30,407 Added 4.52%
702,669 $62.2 Million
Q3 2019

Nov 12, 2019

BUY
$62.98 - $75.72 $6.23 Million - $7.49 Million
98,891 Added 17.25%
672,262 $50.9 Million
Q2 2019

Aug 12, 2019

BUY
$65.7 - $83.98 $9.37 Million - $12 Million
142,676 Added 33.13%
573,371 $41.7 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $341,575 - $402,018
4,428 Added 1.04%
430,695 $34.7 Million
Q4 2018

Feb 13, 2019

BUY
$77.85 - $96.01 $15.8 Million - $19.5 Million
203,246 Added 91.13%
426,267 $39.3 Million
Q3 2018

Nov 13, 2018

SELL
$88.91 - $98.84 $1.48 Million - $1.65 Million
-16,684 Reduced 6.96%
223,021 $21.1 Million
Q2 2018

Aug 14, 2018

SELL
$89.78 - $106.23 $25,317 - $29,956
-282 Reduced 0.12%
239,705 $0
Q1 2018

May 10, 2018

BUY
$92.01 - $123.21 $365,095 - $488,897
3,968 Added 1.68%
239,987 $22.7 Million
Q4 2017

Feb 14, 2018

SELL
$89.56 - $98.21 $2.53 Million - $2.78 Million
-28,279 Reduced 10.7%
236,019 $22.8 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $18.5 Million - $23.6 Million
264,298
264,298 $23.5 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Natixis Advisors, L.P. Portfolio

Follow Natixis Advisors, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.